Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: TAIFd, TAIFc, TAIFb, TAIFa, TAIF, NK4, interleukin 32, IL-32δ, IL-32γ, IL-32β, IL-32α, IL-32gamma, IL-32delta, IL-32beta, IL-32alpha, IL-32 Protein(isoform α), IL32

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 µg | $56 | - | In Stock | |
| 10 µg | $88 | - | In Stock | |
| 20 µg | $142 | - | In Stock | |
| 50 µg | $276 | - | In Stock | |
| 100 µg | $462 | - | In Stock | |
| 200 µg | $791 | 7-10 days | 7-10 days | |
| 500 µg | $1,680 | 7-10 days | 7-10 days | |
| 1 mg | $3,000 | 7-10 days | 7-10 days |
| Bioactivity | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | IL-32 is a recently discovered cytokine that induces various proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the NF-kappaB and p38 MAPK inflammatory signal pathways. It is regulated robustly by other major proinflammatory cytokines and is crucial to inflammation and immune responses. Four of the IL-32 isoforms (alpha, beta, gamma, and delta) are the most representative IL-32 transcripts, and the gamma isoform of IL-32 is the most active, although all isoforms are biologically active. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, Mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and in the human stomach cancer, human lung cancer, and breast cancer tissues. Thus, IL-32 expression might be valuable as a biomarker for cancer. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-His |
| Accession Number | P24001-4 |
| Construction | A DNA sequence encoding the human IL32 isoform alpha (IL32A) (NP_001012651.1) precursor (Met 1-Lys 131) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Met 1 |
| Protein Purity | > 95 % as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| Synonyms | TAIFd, TAIFc, TAIFb, TAIFa, TAIF, NK4, interleukin 32, IL-32δ, IL-32γ, IL-32β, IL-32α, IL-32gamma, IL-32delta, IL-32beta, IL-32alpha, IL-32 Protein(isoform α), IL32 |
| Research Background | IL-32 is a recently discovered cytokine that induces various proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the NF-kappaB and p38 MAPK inflammatory signal pathways. It is regulated robustly by other major proinflammatory cytokines and is crucial to inflammation and immune responses. Four of the IL-32 isoforms (alpha, beta, gamma, and delta) are the most representative IL-32 transcripts, and the gamma isoform of IL-32 is the most active, although all isoforms are biologically active. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, Mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and in the human stomach cancer, human lung cancer, and breast cancer tissues. Thus, IL-32 expression might be valuable as a biomarker for cancer. |
| Molecular Weight | 15.7 kDa (predicted); 20 kDa (reducing condition, due to glycosylation) |
| Shipping | In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice. |
| Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.